Evaxion A (EVAX) Interest Expenses (2020 - 2026)
Evaxion A (EVAX) reported Interest Expenses of -$332000.0 for Q1 2026, up 16.37% on a YoY basis from -$285290.0 in Q1 2025, and up 87.92% quarter-over-quarter from -$2.7 million in Q4 2025.
Evaxion A (EVAX) Interest Expenses (2020 - 2026) Analysis & Trends
Evaxion A has reported Interest Expenses for 7 years, with the latest figure at -$332000.0 in Q1 2026.
- For the quarter ending Q1 2026, Interest Expenses rose 16.37% year-over-year to -$332000.0; the trailing twelve-month figure through Mar 2026 stood at -$5.7 million (down 73.19% YoY), and the FY2025 full-year result was -$5.7 million, down 83.67% from the prior year.
- Interest Expenses for Q1 2026 stood at -$332000.0, up from -$2.7 million in the prior quarter.
- The five-year high for Interest Expenses was -$158000.0 in Q1 2022, with the low at -$2.7 million in Q4 2025.
- Historically, Interest Expenses has averaged -$728352.9 across 5 years, with a median of -$397000.0 in 2025.
- Annual changes were most pronounced in 2022 — Interest Expenses plunged 949.02% — and 2023, when it soared 65.98%.
- Evaxion A's Interest Expenses stood at -$590000.0 in 2022, then sank by 51.69% to -$895000.0 in 2023, then surged by 48.83% to -$458000.0 in 2024, then tumbled by 500.0% to -$2.7 million in 2025, then soared by 87.92% to -$332000.0 in 2026.
- The last three Interest Expenses figures came in at -$332000.0 (Q1 2026), -$2.7 million (Q4 2025), and -$1.4 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -5.50 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -332,000.00 |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 61,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -2,753.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -5.58 Mn |
| 10 | Regeneron Pharmaceuticals | 63.43 Bn | 54.67 Bn | 3.31 Bn | 12.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -332,000.00 |
| Mar 31, 2026 | -332,000.00 |
| Dec 31, 2025 | -2.75 Mn |
| Dec 31, 2025 | -2.75 Mn |
| Sep 30, 2025 | -1.36 Mn |
| Sep 30, 2025 | -1.36 Mn |
| Jun 30, 2025 | -1.23 Mn |
| Jun 30, 2025 | -1.23 Mn |
| Mar 31, 2025 | -397,000.00 |
| Mar 31, 2025 | -397,000.00 |
| Dec 31, 2024 | -458,000.00 |
| Dec 31, 2024 | -458,000.00 |
| Sep 30, 2024 | -384,000.00 |
| Sep 30, 2024 | -384,000.00 |
| Jun 30, 2024 | -2.04 Mn |
| Jun 30, 2024 | -2.04 Mn |
| Mar 31, 2024 | -246,000.00 |
| Mar 31, 2024 | -246,000.00 |
| Dec 31, 2023 | -895,000.00 |
| Dec 31, 2023 | -895,000.00 |